What diseases does erdafitinib treat and its mechanism of action?

ErdafitinibBalversa (erdafitinib) is an oral medicine used to treat bladder cancer in adults. It specifically targets patients who develop genetic changes in the fibroblast growth factor receptor (FGFR) gene after receiving platinum-based chemotherapy.

Erdafitinib is a once-daily, oral fibroblast growth factor receptor (FGFR) kinase inhibitor that binds to and inhibits the enzymatic activities of FGFR1, FGFR2, FGFR3, and FGFR4 based on in vitro data. Erdafitinib also binds to RET, CSF1R, PDGFRA, PDGFRB, FLT4, KIT, and VEGFR2. Erdafitinib inhibits FGFR phosphorylation and signaling and reduces cell viability in cell lines expressing FGFR gene alterations, including point mutations, amplifications, and fusions. Erdafitinib exhibits antitumor activity in FGFR-expressing cell lines and xenograft models derived from tumor types, including bladder cancer.

However, erdafitinib may also cause some adverse reactions, such as digestive system reactions such as nausea, vomiting, and diarrhea, and skin reactions such as dry skin and desquamation. In addition, because drugs inhibit the growth and division of tumor cells, they may also have a certain impact on normal cells, leading to side effects such as thrombocytopenia and leukopenia.

In summary, erdafitinib plays an important role in the treatment of malignant tumors through its unique mechanism of action. Although there are some adverse effects, its effectiveness in controlling tumor growth and spread makes erdafitinib an important drug in the field of modern cancer treatment. Patients should pay close attention to their physical condition during use and communicate with their doctors in a timely manner to adjust the treatment plan.